<a href="https://laohu8.com/S/CLYM">Climb Bio</a> Unveils Promising Clinical Data for Budoprutug in Membranous Nephropathy and Preclinical Results for CLYM116 in IgA Nephropathy at ASN Kidney Week 2025
Climb Bio Inc. has announced upcoming presentations of new data at the 2025 American Society of Nephrology (ASN) Kidney Week, scheduled for November 6-9, 2025, in Houston, Texas. The company will present preclinical data on CLYM116, a novel Fc-engineered anti-APRIL monoclonal antibody in development for IgA nephropathy (IgAN). The data highlight favorable pharmacokinetic and pharmacodynamic properties, including enhanced antibody recycling and sustained reduction of IgA in preclinical models. Additionally, Climb Bio has published long-term follow-up clinical results from its Phase 1b trial of budoprutug, an anti-CD19 monoclonal antibody, in primary membranous nephropathy (pMN). The results indicate long-term control of proteinuria for up to three years after initial dosing, with no further immunosuppressive treatment required in most patients studied. No clinically significant treatment-related adverse events were reported. The abstracts for both programs are now available on the ASN Kidney Week conference website, and the results will be formally presented at the conference.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546929-en) on October 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.